{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '2.2.', 'Study Objectives', '40', '2.2.1.', 'Primary Objective', '40', '2.2.2.', 'Secondary Objective', '40', '2.3.', 'Study Endpoints', '40', '2.3.1.', 'Primary Efficacy Endpoint', '40', '2.3.2.', 'Key Secondary Efficacy Endpoints', '40', '2.3.3.', 'Exploratory Endpoints', '40', '2.3.4.', 'Safety Endpoints', '41', '2.3.5.', 'Pharmacokinetic Endpoint', '41', '3.', 'STUDY DESIGN', '42', '3.1.', 'General Design and Study Schema', '42', '3.1.1.', 'Overall Design and Screening Period', '42', '3.1.2.', 'Screening Period', '42', '3.1.3.', 'Titration Period', '43', '3.1.4.', 'Maintenance Period', '44', '3.1.5.', 'Washout Period and Follow-up', '44', '3.2.', 'Justification for Study Design', '45', '3.3.', 'Primary and Secondary Efficacy Measures and Time Points', '46', '3.3.1.', 'Primary Efficacy Measure and Time Points', '46', '3.3.2.', 'Key Secondary Efficacy Measures and Time Points', '46', '3.3.3.', 'Exploratory Measures and Time Points', '46', '3.4.', 'Safety Measures and Time Points', '46', '3.5.', 'Pharmacokinetic Measures and Time Points', '47', '3.6.', 'Randomization and Blinding', '47', '3.7.', 'Maintenance of Randomization and Blinding', '48', '3.7.1.', 'Randomization', '48', '3.7.2.', 'Blinding/Unblinding', '48', '3.7.3.', 'Independent Data Monitoring Committee', '49', '3.8.', 'Drugs Used in the Study', '49', '3.8.1.', 'IMP', '49', '3.8.2.', 'Placebo', '50', '3.9.', 'Drug Supply and Accountability', '50', '3.9.1.', 'Drug Storage and Security', '50', '22']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '3.9.2.', 'Drug Accountability', '50', '3.10.', 'Duration of Patient Participation and Justification', '50', '3.11.', 'Stopping Rules and Discontinuation Criteria', '50', '3.12.', 'Source Data Recorded on the Case Report Form', '51', '3.13.', 'Study Procedures', '51', '3.13.1.', 'Procedures for Screening and Enrollment', '56', '3.13.1.1.', 'YGTSS Rater Certification', '57', '3.13.2.', 'Procedures Before IMP Treatment (Baseline/Day 1)', '57', '3.13.3.', 'Procedures During IMP Treatment', '59', '3.13.3.1.', 'Titration Period (Baseline/ Day 1 Through 7)', '59', '3.13.3.2.', 'Maintenance Period', '60', '3.13.4.', 'Procedures After IMP Treatment', '62', '3.13.4.1.', 'Week 13', '63', '3.13.4.2.', 'Week 14', '64', '3.13.5.', 'Unscheduled Visits', '64', '4.', 'SELECTION AND WITHDRAWAL OF PATIENTS', '66', '4.1.', 'Patient Inclusion Criteria', '66', '4.2.', 'Patient Exclusion Criteria', '66', '4.3.', 'Justification for Key Inclusion and Exclusion Criteria', '69', '4.4.', 'Withdrawal Criteria and Procedures', '69', '5.', 'TREATMENT OF PATIENTS', '71', '5.1.', 'Drugs Administered During the Study', '71', '5.2.', 'Restrictions', '72', '5.3.', 'Prior and Concomitant Therapy or Medication', '73', '5.4.', 'Procedures for Monitoring Patient Compliance', '73', '5.5.', 'Dose Reduction and Temporary IMP Discontinuation', '74', '5.6.', 'Total Blood Volume', '74', '6.', 'ASSESSMENT OF EFFICACY', '76', '6.1.', 'Primary Efficacy Measure and Justification', '76', '6.2.', 'Key Secondary Efficacy and Exploratory Measures', '76', '6.2.1.', 'Tourette Syndrome-Clinical Global Impression', '76', '6.2.2.', 'Tourette Syndrome-Patient Global Impression of Impact', '76', '6.2.3.', 'Tourette Syndrome-Patient Global Impression of Severity', '77', '23']\n\n###\n\n", "completion": "END"}